Free Trial

Coya Therapeutics Q4 2024 Earnings Report

Coya Therapeutics logo
$5.58 -0.52 (-8.52%)
As of 02:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Coya Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Coya Therapeutics Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.10 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Coya Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Coya Therapeutics Earnings Headlines

Chardan Capital Has Strong Estimate for COYA FY2025 Earnings
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Coya Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coya Therapeutics and other key companies, straight to your email.

About Coya Therapeutics

Coya Therapeutics (NASDAQ:COYA), a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

View Coya Therapeutics Profile

More Earnings Resources from MarketBeat